サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1760692

ホスホジエステラーゼ5阻害剤の世界市場レポート 2025年

Phosphodiesterase 5 Inhibitor Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
ホスホジエステラーゼ5阻害剤の世界市場レポート 2025年
出版日: 2025年07月01日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ホスホジエステラーゼ5阻害剤市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）7.2％で62億5,000万米ドルに成長します。予測期間中、経口・非侵襲的治療に対する需要の高まり、性の健康治療への遠隔医療の採用拡大、個別化医療への注目の高まり、男性不妊治療への注目の高まりなどが成長の原動力になると予想されます。この期間の主要動向としては、併用療法の開発、錠剤併用レジメンとの統合、標的療法の革新、非医薬品代替品の出現、PDE5標的創薬における人工知能の統合などが挙げられます。

勃起不全の有病率の増加がホスホジエステラーゼ5阻害剤市場の成長を牽引すると予想されます。勃起不全（ED）は、満足な性行為を行うのに十分な勃起を達成または維持することが一貫してできないことで定義されます。EDの有病率の増加は、ホルモンバランスの乱れ、特に性機能とパフォーマンスに影響を与えるテストステロンレベルの低下が主要原因です。ホスホジエステラーゼ5阻害剤は、陰茎への血流を促進し、男性が性的刺激に反応して勃起し、それを維持できるようにすることで、勃起不全の治療に役立ちます。例えば、2024年12月、英国の薬局であるLloydsPharmacy Online Doctorは、2023年にNHSがバイアグラの処方箋を約350万枚発行し、2023年9月から2024年8月の間に約2,550万錠の流通につながったと報告しています。このような勃起不全の蔓延が、ホスホジエステラーゼ5阻害剤市場の拡大に拍車をかけています。

調査や臨床検査の増加もホスホジエステラーゼ5阻害剤市場の成長を後押しすると予想されます。臨床検査とは、新しい治療法、医薬品、医療機器の安全性、有効性、潜在的な副作用を評価するために行われるヒトを対象とした調査です。臨床検査の増加は、主に、進化するヘルスケアニーズに対応し、患者の転帰を向上させるための新しい治療に対する需要によってもたらされます。ホスホジエステラーゼ5阻害剤は、勃起不全や肺高血圧症などの疾患に対する治療効果の評価を改善することで、臨床検査のプロセスをサポートし、より的を絞った治療法の開発を支援します。例えば、英国製薬工業協会（ABPI）が2023年11月に発表した報告書によると、英国で毎年開始される産業の臨床検査の総数は、2021年の394検査から2022年には411検査へと4.3％増加しました。その結果、調査と臨床検査の増加がホスホジエステラーゼ5阻害剤市場を前進させると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界のホスホジエステラーゼ5阻害剤PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界のホスホジエステラーゼ5阻害剤市場：成長率分析
  • 世界のホスホジエステラーゼ5阻害剤市場の実績：規模と成長、2019～2024年
  • 世界のホスホジエステラーゼ5阻害剤市場の予測：規模と成長、2024～2029年、2034年
  • 世界のホスホジエステラーゼ5阻害剤総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界のホスホジエステラーゼ5阻害剤市場：薬剤タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • シルデナフィル
  • タダラフィル
  • バルデナフィル
  • アバナフィル
  • その他の薬剤タイプ
  • 世界のホスホジエステラーゼ5阻害剤市場：剤形別、実績と予測、2019～2024年、2024～2029年、2034年
  • 錠剤
  • 注射剤
  • 局所剤
  • 世界のホスホジエステラーゼ5阻害剤市場：用途別、実績と予測、2019～2024年、2024～2029年、2034年
  • 勃起不全
  • 肺動脈高血圧
  • 良性前立腺肥大症
  • その他
  • 世界のホスホジエステラーゼ5阻害剤市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
  • 小売薬局
  • オンライン薬局
  • 病院薬局
  • 世界のホスホジエステラーゼ5阻害剤市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
  • 病院
  • 専門クリニック
  • 在宅ケア
  • 世界のホスホジエステラーゼ5阻害剤市場、シルデナフィルのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • ジェネリックシルデナフィル
  • ブランドシルデナフィル
  • 世界のホスホジエステラーゼ5阻害剤市場、タダラフィルのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • ジェネリックタダラフィル
  • ブランドタダラフィル
  • 世界のホスホジエステラーゼ5阻害剤市場、バルデナフィルのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • ジェネリックバルデナフィル
  • ブランドバルデナフィル
  • 世界のホスホジエステラーゼ5阻害剤市場、アバナフィルのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • ジェネリックアバナフィル
  • ブランドアバナフィル
  • 世界のホスホジエステラーゼ5阻害剤市場、その他の薬剤タイプのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
  • ウデナフィル
  • ロデナフィル
  • ミロデナフィル

第7章 地域別・国別分析

  • 世界のホスホジエステラーゼ5阻害剤市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
  • 世界のホスホジエステラーゼ5阻害剤市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ホスホジエステラーゼ5阻害剤市場：競合情勢
  • ホスホジエステラーゼ5阻害剤市場：企業プロファイル
    • Pfizer Inc.
    • Johnson And Johnson
    • Merck And Co. Inc.
    • Bayer AG
    • GlaxoSmithKline plc

第31章 その他の大手企業と革新的企業

  • Eli Lilly And Company
  • Teva Pharmaceutical Industries Ltd.
  • Boehringer Ingelheim
  • Sun Pharmaceutical Industries Ltd.
  • Apotex Inc
  • Aurobindo Pharma Ltd
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Ltd
  • Lupin Limited
  • Torrent Pharmaceuticals Ltd.
  • Vectura Group
  • Vivus Inc
  • Seoul Pharma
  • Auxilium Pharmaceuticals
  • Metuchen Pharma

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

  • ホスホジエステラーゼ5阻害剤市場、2029年：新たな機会を提供する国
  • ホスホジエステラーゼ5阻害剤市場、2029年：新たな機会を提供するセグメント
  • ホスホジエステラーゼ5阻害剤市場、2029年：成長戦略
    • 市場動向による戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r35569

A phosphodiesterase 5 (PDE5) inhibitor is a type of drug that blocks the enzyme PDE5, which normally breaks down cyclic guanosine monophosphate (cGMP). This molecule plays a key role in relaxing smooth muscle tissue and increasing blood flow. PDE5 inhibitors are commonly used to treat erectile dysfunction and pulmonary arterial hypertension by improving blood flow in targeted areas.

The main types of phosphodiesterase 5 inhibitors include sildenafil, tadalafil, vardenafil, avanafil, and others. Sildenafil is used to treat erectile dysfunction and pulmonary arterial hypertension by relaxing blood vessels and boosting blood flow to specific areas. These medications come in various forms, such as tablets, injectables, and topical applications. They are used to treat conditions like erectile dysfunction, pulmonary arterial hypertension, benign prostatic hyperplasia, and other related disorders. These drugs are distributed through retail pharmacies, online pharmacies, and hospital pharmacies, and are used in hospitals, specialty clinics, and home care settings.

The phosphodiesterase 5 inhibitor market research report is one of a series of new reports from The Business Research Company that provides phosphodiesterase 5 inhibitor market statistics, including the phosphodiesterase 5 inhibitor industry's global market size, regional shares, competitors with the phosphodiesterase 5 inhibitor market share, detailed phosphodiesterase 5 inhibitor market segments, market trends and opportunities, and any further data you may need to thrive in the phosphodiesterase 5 inhibitor market. This phosphodiesterase 5 inhibitor market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The phosphodiesterase 5 inhibitor market size has grown strongly in recent years. It will grow from $4.43 billion in 2024 to $4.74 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to factors such as the increasing prevalence of erectile dysfunction, heightened awareness about sexual health, a growing geriatric population, a rising preference for non-invasive treatment options, and an increase in lifestyle-related diseases.

The phosphodiesterase 5 inhibitor market size is expected to see strong growth in the next few years. It will grow to $6.25 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. In the forecast period, growth is expected to be driven by a rising demand for oral, non-invasive therapeutics, greater adoption of telemedicine for sexual health treatment, an increasing focus on personalized medicine, and a growing emphasis on male fertility treatments. Key trends during this period include the development of combination therapies, integration with combination pill regimens, innovation in targeted therapies, the emergence of non-pharmaceutical alternatives, and the integration of artificial intelligence in PDE5-targeted drug discovery.

The growing prevalence of erectile dysfunction is expected to drive the growth of the phosphodiesterase 5 inhibitor market. Erectile dysfunction (ED) is defined by the consistent inability to achieve or maintain an erection adequate for satisfactory sexual performance. The rising prevalence of ED is largely attributed to hormonal imbalances, particularly low testosterone levels, which affect sexual function and performance. Phosphodiesterase 5 inhibitors help treat erectile dysfunction by enhancing blood flow to the penis, allowing men to achieve and sustain an erection in response to sexual stimulation. For example, in December 2024, LloydsPharmacy Online Doctor, a UK-based pharmacy, reported that in 2023, the NHS issued nearly 3.5 million prescriptions for Viagra, leading to the distribution of about 25.5 million pills between September 2023 and August 2024. This growing prevalence of erectile dysfunction is fueling the expansion of the phosphodiesterase 5 inhibitor market.

The rise in research and clinical trials is also expected to boost the growth of the phosphodiesterase 5 inhibitor market. Clinical trials are research studies involving human participants designed to evaluate the safety, efficacy, and potential side effects of new treatments, drugs, or medical devices. The increase in clinical trials is primarily driven by the demand for new treatments to address evolving healthcare needs and enhance patient outcomes. Phosphodiesterase 5 inhibitors support the clinical trial process by improving the evaluation of therapeutic efficacy for conditions like erectile dysfunction and pulmonary hypertension, thus aiding the development of more targeted treatments. For instance, a report from the Association of the British Pharmaceutical Industry (ABPI) in November 2023 noted that the total number of industry clinical trials initiated annually in the UK rose by 4.3%, from 394 trials in 2021 to 411 in 2022. As a result, the growth in research and clinical trials is expected to propel the phosphodiesterase 5 inhibitor market forward.

Major companies in the phosphodiesterase 5 inhibitor market are focusing on developing innovative products, such as generic versions of Stendra. These generics contain the same active ingredient, avanafil, and help treat erectile dysfunction by inhibiting the PDE5 enzyme, which enhances blood flow to the penis. In October 2024, Camber Pharmaceuticals, Inc., a US-based pharmaceutical company, launched Avanafil tablets in 50 mg, 100 mg, and 200 mg strengths, each available in 30-count bottles. Avanafil works by improving blood flow to the penis during sexual stimulation, with effects typically felt within 15 minutes and lasting for more than six hours.

Major players in the phosphodiesterase 5 inhibitor market are Pfizer Inc., Johnson And Johnson, Merck And Co. Inc., Bayer AG, GlaxoSmithKline plc, Eli Lilly And Company, Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Sun Pharmaceutical Industries Ltd., Apotex Inc, Aurobindo Pharma Ltd, Dr. Reddy's Laboratories Ltd., Cipla Ltd, Lupin Limited, Torrent Pharmaceuticals Ltd., Vectura Group, Vivus Inc, Seoul Pharma, Auxilium Pharmaceuticals, Metuchen Pharma.

North America was the largest region in the phosphodiesterase 5 inhibitor market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in phosphodiesterase 5 inhibitor report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the phosphodiesterase 5 inhibitor market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The phosphodiesterase 5 inhibitor market consists of sales of products including sildenafil, tadalafil, vardenafil, avanafil, and lodenafil. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Phosphodiesterase 5 Inhibitor Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on phosphodiesterase 5 inhibitor market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for phosphodiesterase 5 inhibitor ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The phosphodiesterase 5 inhibitor market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Drug Type: Sildenafil; Tadalafil; Vardenafil; Avanafil; Other Drug Types
  • 2) By Dosage Form: Tablets; Injectables; Topical Applications
  • 3) By Application: Erectile Dysfunction; Pulmonary Arterial Hypertension; Benign Prostatic Hyperplasia; Other Applications
  • 4) By Distribution Channel: Retail Pharmacies; Online Pharmacies; Hospital Pharmacies
  • 5) By End-User: Hospitals; Specialty Clinics; Homecare Settings
  • Subsegments:
  • 1) By Sildenafil: Generic Sildenafil; Branded Sildenafil
  • 2) By Tadalafil: Generic Tadalafil; Branded Tadalafil
  • 3) By Vardenafil: Generic Vardenafil; Branded Vardenafil
  • 4) By AvanafilP: Generic Avanafil; Branded Avanafil
  • 5) By Other Drug Types: Udenafil; Lodenafil; Mirodenafil
  • Companies Mentioned: Pfizer Inc.; Johnson And Johnson; Merck And Co. Inc.; Bayer AG; GlaxoSmithKline plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Phosphodiesterase 5 Inhibitor Market Characteristics

3. Phosphodiesterase 5 Inhibitor Market Trends And Strategies

4. Phosphodiesterase 5 Inhibitor Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Phosphodiesterase 5 Inhibitor Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Phosphodiesterase 5 Inhibitor PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Phosphodiesterase 5 Inhibitor Market Growth Rate Analysis
  • 5.4. Global Phosphodiesterase 5 Inhibitor Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Phosphodiesterase 5 Inhibitor Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Phosphodiesterase 5 Inhibitor Total Addressable Market (TAM)

6. Phosphodiesterase 5 Inhibitor Market Segmentation

  • 6.1. Global Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Sildenafil
  • Tadalafil
  • Vardenafil
  • Avanafil
  • Other Drug Types
  • 6.2. Global Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Tablets
  • Injectables
  • Topical Applications
  • 6.3. Global Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Erectile Dysfunction
  • Pulmonary Arterial Hypertension
  • Benign Prostatic Hyperplasia
  • Other Applications
  • 6.4. Global Phosphodiesterase 5 Inhibitor Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies
  • 6.5. Global Phosphodiesterase 5 Inhibitor Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • 6.6. Global Phosphodiesterase 5 Inhibitor Market, Sub-Segmentation Of Sildenafil, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Generic Sildenafil
  • Branded Sildenafil
  • 6.7. Global Phosphodiesterase 5 Inhibitor Market, Sub-Segmentation Of Tadalafil, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Generic Tadalafil
  • Branded Tadalafil
  • 6.8. Global Phosphodiesterase 5 Inhibitor Market, Sub-Segmentation Of Vardenafil, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Generic Vardenafil
  • Branded Vardenafil
  • 6.9. Global Phosphodiesterase 5 Inhibitor Market, Sub-Segmentation Of Avanafil, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Generic Avanafil
  • Branded Avanafil
  • 6.10. Global Phosphodiesterase 5 Inhibitor Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Udenafil
  • Lodenafil
  • Mirodenafil

7. Phosphodiesterase 5 Inhibitor Market Regional And Country Analysis

  • 7.1. Global Phosphodiesterase 5 Inhibitor Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Phosphodiesterase 5 Inhibitor Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Phosphodiesterase 5 Inhibitor Market

  • 8.1. Asia-Pacific Phosphodiesterase 5 Inhibitor Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Phosphodiesterase 5 Inhibitor Market

  • 9.1. China Phosphodiesterase 5 Inhibitor Market Overview
  • 9.2. China Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Phosphodiesterase 5 Inhibitor Market

  • 10.1. India Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Phosphodiesterase 5 Inhibitor Market

  • 11.1. Japan Phosphodiesterase 5 Inhibitor Market Overview
  • 11.2. Japan Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Phosphodiesterase 5 Inhibitor Market

  • 12.1. Australia Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Phosphodiesterase 5 Inhibitor Market

  • 13.1. Indonesia Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Phosphodiesterase 5 Inhibitor Market

  • 14.1. South Korea Phosphodiesterase 5 Inhibitor Market Overview
  • 14.2. South Korea Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Phosphodiesterase 5 Inhibitor Market

  • 15.1. Western Europe Phosphodiesterase 5 Inhibitor Market Overview
  • 15.2. Western Europe Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Phosphodiesterase 5 Inhibitor Market

  • 16.1. UK Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Phosphodiesterase 5 Inhibitor Market

  • 17.1. Germany Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Phosphodiesterase 5 Inhibitor Market

  • 18.1. France Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Phosphodiesterase 5 Inhibitor Market

  • 19.1. Italy Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Phosphodiesterase 5 Inhibitor Market

  • 20.1. Spain Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Phosphodiesterase 5 Inhibitor Market

  • 21.1. Eastern Europe Phosphodiesterase 5 Inhibitor Market Overview
  • 21.2. Eastern Europe Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Phosphodiesterase 5 Inhibitor Market

  • 22.1. Russia Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Phosphodiesterase 5 Inhibitor Market

  • 23.1. North America Phosphodiesterase 5 Inhibitor Market Overview
  • 23.2. North America Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Phosphodiesterase 5 Inhibitor Market

  • 24.1. USA Phosphodiesterase 5 Inhibitor Market Overview
  • 24.2. USA Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Phosphodiesterase 5 Inhibitor Market

  • 25.1. Canada Phosphodiesterase 5 Inhibitor Market Overview
  • 25.2. Canada Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Phosphodiesterase 5 Inhibitor Market

  • 26.1. South America Phosphodiesterase 5 Inhibitor Market Overview
  • 26.2. South America Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Phosphodiesterase 5 Inhibitor Market

  • 27.1. Brazil Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Phosphodiesterase 5 Inhibitor Market

  • 28.1. Middle East Phosphodiesterase 5 Inhibitor Market Overview
  • 28.2. Middle East Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Phosphodiesterase 5 Inhibitor Market

  • 29.1. Africa Phosphodiesterase 5 Inhibitor Market Overview
  • 29.2. Africa Phosphodiesterase 5 Inhibitor Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Phosphodiesterase 5 Inhibitor Market, Segmentation By Dosage Form, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Phosphodiesterase 5 Inhibitor Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Phosphodiesterase 5 Inhibitor Market Competitive Landscape And Company Profiles

  • 30.1. Phosphodiesterase 5 Inhibitor Market Competitive Landscape
  • 30.2. Phosphodiesterase 5 Inhibitor Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. Phosphodiesterase 5 Inhibitor Market Other Major And Innovative Companies

  • 31.1. Eli Lilly And Company
  • 31.2. Teva Pharmaceutical Industries Ltd.
  • 31.3. Boehringer Ingelheim
  • 31.4. Sun Pharmaceutical Industries Ltd.
  • 31.5. Apotex Inc
  • 31.6. Aurobindo Pharma Ltd
  • 31.7. Dr. Reddy's Laboratories Ltd.
  • 31.8. Cipla Ltd
  • 31.9. Lupin Limited
  • 31.10. Torrent Pharmaceuticals Ltd.
  • 31.11. Vectura Group
  • 31.12. Vivus Inc
  • 31.13. Seoul Pharma
  • 31.14. Auxilium Pharmaceuticals
  • 31.15. Metuchen Pharma

32. Global Phosphodiesterase 5 Inhibitor Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Phosphodiesterase 5 Inhibitor Market

34. Recent Developments In The Phosphodiesterase 5 Inhibitor Market

35. Phosphodiesterase 5 Inhibitor Market High Potential Countries, Segments and Strategies

  • 35.1 Phosphodiesterase 5 Inhibitor Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Phosphodiesterase 5 Inhibitor Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Phosphodiesterase 5 Inhibitor Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer